With thanks to Global Health Now. Comment from me below.
'About $130 million was spent on Ivermectin prescriptions over a 12-month period, researchers have found - suggesting that US insuurers heavily subsidized the costs of the drug despite its ineffectiveness to treat COVID-19.'
CITATION: US Insurer Spending on Ivermectin Prescriptions for COVID-19
Kao-Ping Chua, MD, PhD1; Rena M. Conti, PhD2; Nora V. Becker, MD, PhD3
January 13, 2022 JAMA. Published online January 13, 2022. doi:10.1001/jama.2021.24352
COMMENT (NPW): Financing of health care in the US is based on insurance, whereby payments are expected to cover evidence-based care only. This paper shows that this is not in fact the case: the US system leads to large amounts of expenditure on ineffective treatments.
Neil Pakenham-Walsh, HIFA Coordinator, neil@hifa.org www.hifa.org
